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INTRODUCTION 
Anorectal melanoma is a rare form of melanoma 
affecting the anus and/or rectum. It accounts for 0.25-
1.25% of all anorectal malignancies and is the third most 
common site for melanoma, after the skin and eye.1 
Anorectal melanoma affects mainly people aged 50-80 
years, with peak incidence in the sixth and seventh 
decades of life. There are no significant gender 
differences, whereas the Caucasian race seems to be more 
frequently affected than African American individuals.1 
Diagnosis is often delayed, since symptoms are 
frequently nonspecific and easily mistaken for more 
benign conditions, such as hemorrhoids. Radical surgery 
is the mainstay of treatment, while the role of adjuvant 
chemotherapy, immune therapy and radiotherapy is yet to 
be established. Prognosis is therefore extremely poor with 
an average survival of 8-24 months and a 5-year survival 
rate of 10-15%.1,2 
CASE REPORT 
A 75-year-old Caucasian woman was seen in April 2011 
with a two-month history of occasional rectal bleeding 
and moderate anal pain. Her medical history was 
remarkable for ischemic cardiomyopathy and obesity 
(body mass index 30 kg/m2). On a more accurate 
anamnesis, she reported the removal of a blue nevus of 
the foot dorsum about ten years earlier. She denied any 
other significant personal and family history. 
Considering the clinical findings, the patient underwent a 
colonoscopy with removal of three polyps with low-grade 
dysplasia. The endoscopy also revealed a blackish 
perianal lesion, fragile and easy to bleed, on which 
biopsies were taken (Figure 1). Histopathologic findings 
were consistent with a melanomatous lesion. On lab tests, 
S-100 protein was slightly positive. An accurate staging 
of the disease was also performed by means of ultrasound 
of the regional lymph nodes, chest radiography, and 
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whole-body PET-CT, with no evidence of distant 
metastases. 
 
Figure 1: Primitive rectal melanoma discovered 
during colonoscopy. 
After a thorough multidisciplinary team discussion 
(including surgeons, gastroenterologists, dermatologists 
and oncologists), a conservative approach was proposed 
and the patient underwent a trans-anal excision of the 
melanomatous lesion. Pathologic examination of the 
resected specimen confirmed the presence of a nodular, 
ulcerated, mucosal melanoma, with low mitotic index and 
Breslow index of 10 mm, invading the submucosa and 
muscle tunica of the rectum, with perilesional lympho-
plasmacellular infiltration and no inflammatory intra-
lesional infiltrates. Excision surgical margins were 
disease-free. The post-operative course was uneventful, 
albeit the patient briefly required medication for a wound 
dehiscence. Soon afterwards, she was started on adjuvant 
immunotherapy with interferon-gamma according to the 
Kirkwood protocol (IntronA 3 MU s.c. three times per 
week). Considering the good tolerance to the drug, the 
patient continued the immunotherapy for 18 months, until 
December 2012. 
In September 2012, at 15 months from surgery, the 
patient presented at a follow-up examination complaining 
rectal bleeding. A colonoscopy was consequently 
performed and a local relapse of disease was found 
(Figure 2). 
There was no evidence of metastatic disease on 
preoperative imaging and the patient underwent an 
abdominoperineal resection (Miles operation). She well 
tolerated the surgical procedure without any 
complications. Final histopathologic analysis showed a 
recurrent rectal melanoma, nodular and ulcerated, with 
free resection margins and metastatic deposit in one 
mesorectal lymph node out of 20 identified.  
In July 2013, suspicious bilateral inguinal 
lymphadenopathy was noticed and an ultrasound-guided 
fine needle aspiration (FNA) was performed. Cytologic 
examination confirmed the suspect of bilaterally 
metastatic disease, while on thoraco-abdominal imaging 
no evidence of further secondary localizations was found. 
Thus, the patient underwent bilateral inguinal 
lymphadenectomy. To date, she is still alive and currently 
disease-free. 
 
Figure 2: Recurrence of rectal melanoma diagnosed 
during follow-up colonoscopy. 
DISCUSSION 
Primary malignant melanoma of the anus and rectum is a 
rare form of melanoma associated with a poor prognosis. 
It represents 0.25-1.25% of all anorectal malignancies 
and it accounts for less than 1% of all melanomas, 
although it is the third most common location after 
cutaneous and ocular sites.1,2 The incidence of primary 
anorectal melanoma is continuously increasing over 
time.3 It arises from melanocytes, which are cells derived 
from the embryologic neural crest and reside primarily in 
the skin, but can also be found in the eyes and mucosal 
surfaces. 
Anorectal melanoma was first reported by Moore in 
1857.4 The clinical and pathological features were first 
reported in 1963 by Morson and Volkstadt, who outlined 
eleven different types of “implant” of the lesion in the 
anal canal, relatively to its position with respect to the 
dentate line. Indeed, melanomatous lesions can affect the 
anal canal, the rectum, or both, with the majority 
occurring within 6 cm of the anal rim.5,6 
The exact causes of anorectal melanoma are not 
established yet. Sunlight exposure, particularly UVB 
radiation, is a well-known risk factor for cutaneous 
melanoma, but to date it is still unclear what triggers the 
development of mucosal melanoma, and specifically 
anorectal melanoma. Interestingly, some authors have 
suggested a possible association with HIV and HHV-8 
infection, but data are still controversial.7-9 
Anorectal melanoma commonly affects the elderly in 
their sixth or seventh decade of life, with a 1.7 - fold 
higher prevalence in Caucasians than in African 
Americans.1 Some authors report a possible female 
predominance, but most publications do not suggest 
significant gender differences and individual series are 
too small to draw definitive conclusions.7-11 
Lesions are usually polypoid, often ulcerated and easy to 
bleed, with or without pigmentation.12 Melanin pigment 
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within the malignant cells and junctional changes, e.g. the 
presence of atypical epidermoid cells or pleomorphic 
spindle cells adjacent to the focus of malignant tumor, 
help histologic diagnosis. Immunochemistry panels can 
also support the diagnosis. Indeed, melanoma antigens S-
100, HMB-45, and vimentin are stained positively in 
78%, 94%, and 100% of tumors respectively, while 
monoclonal antibodies to CEA can help to distinguish 
from a poorly differentiated epidermoid carcinoma.11 
Diagnosis of anorectal melanoma is clinically challenging 
because symptoms are often nonspecific. Patients 
commonly present with rectal bleeding, anorectal pain or 
discomfort, change in bowel habits, and prolapsed tumor 
mass. If metastatic disease is present, weight loss, 
anemia, fatigue, groin swelling, or pelvic masses may be 
present as well.11,13-16 Patients are often misdiagnosed 
with more common diseases, including hemorrhoids, 
polyp, adenocarcinoma, or rectal ulcer.6 A timely 
diagnosis of anorectal melanoma is made even more 
difficult by the fact that up to 80% of lesions lack 
obvious pigmentation and up to 20% of tumors are even 
histologically amelanotic.5,17 
Therefore, patients presenting with bleeding and/or 
anorectal pain should undergo a thorough examination of 
the colon and rectum, and biopsies of any suspicious 
lesion should be obtained. Rarely, anal melanoma can be 
identified during routing pathologic examination of a 
hemorrhoidectomy specimen.18 Important staging tools 
include ultrasound of regional lymph nodes, CT scan of 
the abdomen and chest, and pelvic MRI scan. The best 
imaging exam to detect lymph node metastasis and 
distant metastasis is the PET-CT, which appeared to be 
superior to CT scan.19 
Because of the delays in diagnosis and the aggressive 
nature of the disease, patients with anorectal melanoma 
frequently present with advanced disease. Common sites 
of metastasis are the regional lymph nodes, liver and 
lungs.20 Average survival is of 8-24 months, with a 5-year 
survival rate of 10-15%.21 Prognostic factors include the 
stage of the disease at the time of diagnosis and the tumor 
thickness.22,23 
At present, surgery represents the mainstay of treatment, 
but the optimal approach is still controversial. Surgical 
intervention includes wide local excision (WLE) and 
abdomino-perineal resection (APR).19,24 Several studies 
failed to demonstrate any survival advantage with either 
approach.23,25-27 Chen et al. recommended surgery as the 
optimal treatment for local- and regional-stage anorectal 
melanoma, but not in case of distant metastasis.3 
Recently, some authors suggested the initial treatment of 
choice to be WLE, because more radical approaches did 
not show any survival advantage and conservative 
surgery also avoid the need for a permanent colostomy.24 
On the other side, local disease appears to be more 
effectively controlled with APR.14,28,29 Likewise, current 
guidelines are not clear regarding sentinel lymph node 
biopsy. Although feasible and the preferred method of 
nodal staging for cutaneous melanoma, its role for 
staging of anal melanoma remains uncertain.11,30-32 
In a recent paper by Ciarrocchi et al. was reported that 
metastasis to loco-regional lymph-nodes was an 
important prognostic factor, but lymphadenectomy did 
not improve survival.33 In our patient the bilateral 
lymphadenectomy appeared to be curative, since she is 
still alive after more than three years from the surgical 
procedure. 
As for adjuvant therapies, there are no standard approved 
regimens and strategies are mainly aimed at local control 
of the disease. Radiotherapy has been reported to 
improve local control after WLE and appears beneficial 
for sphincter preservation.12,14,24,32 Patients with 
metastatic anorectal melanoma may benefit from 
combination chemotherapy. Many agents have been 
studied, including dacarbazine, vincristine, and 
interferon, but none has shown significant survival 
benefit for anorectal melanoma.11 
CONCLUSION 
Anorectal melanoma is a rare and aggressive malignancy 
affecting mainly elderly people. Early diagnosis and 
treatment are crucial, but symptoms are frequently 
aspecific and vague. Prognosis is generally poor, with 
distant metastases being a common and fatal 
development. Due to the rarity of the disease and lack of 
prospective randomized trials, the ideal multimodality 
therapy for anorectal melanoma is yet to be defined. 
Surgery is currently the mainstay of treatment and a more 
conservative approach should be preferred whenever 
technically feasible, in order to minimize patient 
morbidity and maximize quality of life. Inguinal 
lymphadenectomy should be reserved for clinically 
palpable disease, whereas the role of adjuvant therapies is 
still under debate.  
As was the case of our patient, the treatment of choice at 
the beginning was defined by a more conservative 
surgical approach associated to systemic immunotherapy. 
A close follow-up subsequently allowed an early 
identification of the local relapse and a complete R0 
surgical excision was completed. 
According to our personal experience, given the lack of 
adequate international guidelines, we recommend 
defining a tailored treatment by thorough 
multidisciplinary discussion, which should include 
specialists in oncology, dermatology, pathology, and 
surgery, as well as taking into account the patient 
personal preference. 
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